Table 2: Clinical and immunological characteristics of study participants.
Variables |
Case n (%) |
Control n (%) |
Total n (%) |
P-Value |
CTX prophylaxis |
Yes |
75 (62.5) |
70 (58.33) |
145(60.42) |
0.253 |
No |
45 (37.5) |
50 (41.67) |
95 (39.58) |
INH prophylaxis |
Yes |
51 (42.5) |
46 (38.33) |
97 (40.42) |
0.255 |
No |
69 (57.5) |
74 (61.67) |
143(59.58) |
TB treatment history |
Yes |
73(60.83) |
75 (62.5) |
148(61.67) |
0.433 |
No |
47 (39.17) |
45 (37.5) |
92(38.33) |
Type of TB |
Pulmonary |
34 (46.57) |
29 (38.67) |
63 (42.57) |
0.426 |
Disseminated |
21(28.76) |
22 (29.33) |
43 (29.06) |
Unknown |
18 (24.65) |
24 (32) |
42(28.37) |
Clinical stage(WHO) |
Stage I |
15 (12.5) |
18 (15) |
33(13.76) |
0.018 |
Stage II |
30(25) |
35 (29.17) |
65 (27.08) |
Stage III |
44 (36.67) |
48 (40) |
92 (38.33) |
Stage IV |
31 (25.83) |
19 (15.83) |
50 (20.83) |
Eligibility reason |
CD4+ count |
36 (30) |
47 (39.17) |
83 (34.58) |
0.039 |
Clinical |
27 (22.5) |
18 (15) |
45 (18.75) |
CD4+ count & clinical |
57 (47.5) |
55 (45.83) |
112 (46.67) |
Baseline CD4+ count (cells/µL) |
Median |
184.50 |
177 |
182.00 |
0.564 |
<200 |
59 (49.17) |
58 (48.33) |
117 (48.75) |
200 −349 |
33 (27.5) |
36 (30) |
69 (28.75) |
350 − 499 |
15 (12.5) |
15 (12.5) |
30 (12.5) |
≥500 |
13(10.83) |
11 (9.17) |
24 (10) |
Time elapsed till HAART initiation (in months) |
Within the same month |
51(42.5) |
39 (32.5) |
90 (37.5) |
0.038 |
1-24 |
45(37.5) |
45 (37.5) |
90 37.5 |
≥24 |
24 (20) |
36 (30) |
60(25) |
Median duration on HAART (in months) |
73 |
76.50 |
|
0.604 |
Median duration with HIV (in months) |
80 |
94.50 |
|
0.140 |
Functional Status |
Working |
90 (75) |
93 (77.5) |
183(76.25) |
0.305 |
Ambulatory |
30 (25) |
27 (22.5 |
57 (23.75) |
Regimen Change |
Yes |
68 (56.67) |
72 (60) |
140(58.33) |
0.32 |
No |
52 (43.33) |
48 (40) |
100 (41.67) |
CTX-Cotrimoxazole, INH- Isoniazid, TB- Tuberculosis, WHO- World Health Organization, CDC- Centers for Disease Control and Prevention; SD- Standard Deviation, CD4+- Cluster Differentiation, HAART- Highly Active Antiretroviral Therapy